Genetically Engineered‐Cell‐Membrane Nanovesicles for Cancer Immunotherapy

Qinzhen Cheng,Yong Kang,Bin Yao,Jinrui Dong,Yalan Zhu,Yiling He,Xiaoyuan Ji
DOI: https://doi.org/10.1002/advs.202302131
IF: 15.1
2023-07-08
Advanced Science
Abstract:Enabled by recent advances in nanotechnology and materials science, genetically engineered‐cell‐membrane nanovesicles (GCMNs) hold great potential to provide better solutions for cancer immunotherapy. By reviewing the state‐of‐the‐art GCMNs and highlighting the promising technology development, this review intends to spark further research and development activity in this critical research area. The advent of immunotherapy has marked a new era in cancer treatment, offering significant clinical benefits. Cell membrane as drug delivery materials has played a crucial role in enhancing cancer therapy because of their inherent biocompatibility and negligible immunogenicity. Different cell membranes are prepared into cell membrane nanovesicles (CMNs), but CMNs have limitations such as inefficient targeting ability, low efficacy, and unpredictable side effects. Genetic engineering has deepened the critical role of CMNs in cancer immunotherapy, enabling genetically engineered‐CMN (GCMN)‐based therapeutics. To date, CMNs that are surface modified by various functional proteins have been developed through genetic engineering. Herein, a brief overview of surface engineering strategies for CMNs and the features of various membrane sources is discussed, followed by a description of GCMN preparation methods. The application of GCMNs in cancer immunotherapy directed at different immune targets is addressed as are the challenges and prospects of GCMNs in clinical translation.
materials science, multidisciplinary,nanoscience & nanotechnology,chemistry
What problem does this paper attempt to address?